This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and…
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning. The company announced that it has received a “refuse to file letter” from the FDA regarding its New…
Billionaire and activist investor Carl Icahn has made some large changes to his portfolio holdings. He and Icahn Capital, L.P. have not been immune to the market sell-off as you have seen…
Biogen Idec (NASDAQ: BIIB) is coming under fire from activist investor Carl Icahn this morning. A release came out as a "shareholder proposal" from Icahn Partners LP. He is asking for four…
Douglas A. McIntyre Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know is if these results — or more importantly its guidance — show…
These are some of the top pre-market downgrades and cautious calls we have seen from Wall Street analysts this Wednesday morning: Amylin Pharmaceuticals (AMLN) Cut to Sell at Canaccord Adams. Biogen Idec…
These are some of the top analyst upgrades and positive research calls we have seen from Wall Street analysts with more than two hours until the market opens this Tuesday morning: ARM…
It is still fairly thin in analyst upgrades and downgrades as this week marks the return of investment banking and research departments from what is nearly a two-week hiatus. Here are the…
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to acquire a…
Biogen Idec Inc. (NASDAQ: BIIB) just came out with an SEC filing showing that on December 11, 2008, regulatory agencies were notified of a confirmed case of progressive multifocal leukoencephalopathy. In other…
Douglas A. McIntyre It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be…
These are some of the top pre-market upgrades from analysts which we have seen in the early hours this Monday morning: Acorda Therapeutics (ACOR) Raised to Outperform at Baird. Biogen Idec (BIIB)…
Biogen Idec Inc. (NASDAQ: BIIB has notified regulatory agencies of a confirmed case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient treated with TYSABRI .
Douglas A. McIntyre Below are some of the top analyst calls we are seeing from Wall Street firms this Thursday morning: Biogen Idec (BIIB) Raised to Buy at Lazard. Cowen (COWN) Raised to Outperform at…
These are some of the early bird analyst upgrades and positive calls we are seeing this Thursday morning with more than two hours to the open: Auxilium Pharma (AUXL) Started as Outperform…
